Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Biomed Res Int. 2021 Dec 3;2021:9171715. doi: 10.1155/2021/9171715. eCollection 2021.
The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria.
We systematically searched PubMed and Embase for studies that compared HCQ and other treatments to reduce proteinuria in patients with IgA nephropathy up to June 2021. Mean ± SD of percentage change and level of proteinuria was calculated.
A total of 5 studies with 587 participants were included. IgA nephropathy patients who received HCQ were at a lower level of mean proteinuria at 6 months. However, there was no statistical difference between HCQ and control group considering percentage reduction in proteinuria. The long-term therapeutic effect of HCQ might be inferior to HCQ and renin-angiotensin-aldosterone system inhibition.
HCQ might play a role in the reduction of proteinuria in IgA nephropathy patients. The addition of HCQ to other immunosuppressive agents should be clarified further.
本荟萃分析旨在探讨羟氯喹(HCQ)在 IgA 肾病患者蛋白尿方面的疗效。
我们系统地检索了 PubMed 和 Embase 数据库,以查找截至 2021 年 6 月比较 HCQ 与其他治疗方法以降低 IgA 肾病患者蛋白尿的研究。计算蛋白尿百分比变化和水平的均数 ± 标准差。
共纳入 5 项研究,共计 587 名参与者。接受 HCQ 治疗的 IgA 肾病患者在 6 个月时蛋白尿水平较低。然而,考虑到蛋白尿减少的百分比,HCQ 与对照组之间没有统计学差异。HCQ 的长期治疗效果可能不如 HCQ 和肾素-血管紧张素-醛固酮系统抑制。
HCQ 可能在降低 IgA 肾病患者蛋白尿方面发挥作用。应进一步阐明 HCQ 联合其他免疫抑制剂的治疗效果。